As many as 1 in 3 women are expected to be negatively affected by HMB during their life but knowledge of the condition is poor.2,3 As such, many women are unaware that there are treatment options available for HMB2 – you can help her to speak up with three key questions:
See how these same three questions can help you to determine individualised treatment plans for your patients through these case studies
- HELP Group. Heavy menstrual bleeding e-learning. Available at: https://uk.heavy-menstrual-bleeding.com/index.php?WT.mc_id=Mediconf_2018. Last accessed: October 2019.
- Bitzer J, et al. Open access Journal of Contraception, 2013;4:21–28.
- Hurskainen R, et al. Acta Obstetricia et Gynecologica 2007;86:749–757.
Once 'bothersome bleeding' has been identified, follow the HELP diagnostic pathway for HMB
NICE recommends Mirena® as a first-line pharmaceutical treatment for HMB with no identified pathology.1
- Provides effective relief from idiopathic menorrhagia.2
- Achieves menstrual blood loss reduction of up to 96%.3
- Reduced bleeding promotes the increase of blood haemoglobin levels.2
- Improves quality of life more than usual medical treatments (tranexamic acid, mefenamic acid, combined oestrogen-progestogen or progesterone alone).4
- Totally or occasionally absent menstruation has been associated with prolonged continuation with Mirena®.5
- May effectively manage bleeding problems during the transition through menopause.6
- NICE clinical guidance NG88. Heavy menstrual bleeding: assessment and management, March 2018. Available at: https://www.nice.org.uk/guidance/ng88. Last accessed: October 2019.
- Bayer PLC. Mirena® Summary of Product Characteristics, 2018.
- Stewart A, et al. Br J Obs Gyn 2001;108:74–86.
- Gupta J, et al. N Engl J Med 2013;368:128–137.
- Backman T, et al. Br J Obs Gyn 2000;107:335–339.
- Depypere H and Inki P. Climacteric 2015;18:1–13.